Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
SINGAPORE, Jul 24, 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc.
Global BioLife's Director of Scientific Initiatives Mr Daryl L.Thompson was invited to present the new formula to health ambassadors from around the world at Harvard Medical School's Global Health Catalyst Summit, an annual event that focuses on initiatives to eliminate global health disparities.
Clinical trial results show that Laetose is a new sugar product that reduces its negative impact on the body. It is a healthier sweetener that is identical to regular sugar in taste, texture and shelf life, but a naturally modified table sugar which carries 30% fewer calories and a glycemic index score of 53 as compared to a score of 100 in glucose.
"You can think of Laetose as Sugar 2.0. It is more than a low-calorie sugar, but rather a solution to sugar itself in that it was specifically formulated to fight disease," said Mr Thompson. "We've developed a formula that uses sugar the way nature intended. Laetose tastes and performs exactly like sugar as a food ingredient but it is better accepted by the body."
Mr Thompson announced the completion of human trials on Laetose, conducted at one of the foremost laboratories in the world to measure glycemic index, with additional independent testing conducted at Charles River Laboratories showing Laetose halts stimulation of lipopolysaccharide inflammation which leads to Metabolic Endotoxemia, the root of metabolic-driven disease.
Global BioLife has partnered with Quality Candy Company LLC to form a joint venture, Sweet Sense Inc., to produce and market Laetose. Sweet Sense refined the formula at its production facility and created a scalable manufacturing process for Laetose.
"Clinical trials are complete, patents have been filed and the product is ready for full-scale production," said Mr Thompson. Sweet Sense is looking to licence Laetose and is sourcing for companies with the ability to introduce Laetose into multiple food products around the world.
Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, there is no certainty or assurance that Laetose will be licensed or come close to monetisation. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about actions they should take.
About Singapore eDevelopment Ltd Incorporated on 9 September 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email: contact@sed.com.sg.
About Global BioLife Inc. Global BioLife Inc. (GBLI) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned subsidiary of Singapore BioMedical Pte. Ltd., itself a wholly-owned subsidiary of Singapore eDevelopment Ltd, a company listed on the SGX. Remaining shares are held by Global Research and Discovery Group Scientific LLC (GRDGS) at 20% and ASX-listed Holista CollTech Limited at 10%.
GBLI strives to leverage its scientific know-how and intellectual property to provide solutions to problems that have been plaguing the biomedical field for decades. Tapping the scientific expertise of GRDGS and Holista, GBLI pledges a concerted effort in R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with partners to develop second generation, DEET alternative mosquito defense technologies to protect against diseases such as Zika, Dengue, West Nile Virus and Malaria. For more information, please visit: http://www.globalbiolife.com.
Source: Alset International Ltd Sectors: Daily Finance, Food & Beverage, BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants Mar 29, 2024 11:00 JST
| Fujitsu Selected as CDP Supplier Engagement Leader Mar 29, 2024 10:28 JST
| Mazda Production and Sales Results for February 2024 Mar 29, 2024 10:00 JST
| Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System Mar 28, 2024 16:45 JST
| Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan Mar 28, 2024 13:52 JST
| Toyota Releases Sales, Production, and Export Results for February 2024 Mar 28, 2024 13:35 JST
| TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants Mar 28, 2024 03:00 JST
| PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles Mar 27, 2024 15:13 JST
| NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System Mar 27, 2024 15:00 JST
| TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building Mar 27, 2024 03:00 JST
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry Mar 26, 2024 19:04 JST
| La Banque Postale and JCB join forces to elevate payments experience for travellers in France Mar 26, 2024 15:00 JST
| Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin' Mar 26, 2024 10:24 JST
| NEC develops marketing strategy planning & effectiveness simulation technology using generative AI Mar 25, 2024 10:08 JST
| Toyota to Open New Tokyo Head Office in Shinagawa in FY2030 Mar 22, 2024 16:15 JST
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year Mar 22, 2024 16:04 JST
| Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle Mar 22, 2024 15:34 JST
| JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card Mar 22, 2024 15:00 JST
| JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan Mar 22, 2024 12:00 JST
| NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber Mar 22, 2024 08:38 JST
|
More Latest Release >>
|